Welcome to our dedicated page for ANTERIS TECHNOLOGIES GLOBAL SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anteris Technologies Global Corp. (AVR) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, giving investors a detailed view of its structural heart business and capital markets activity. As a medical instruments and supplies company focused on the DurAVR Transcatheter Heart Valve (THV) System, Anteris uses its filings to describe its technology, clinical programs and financial profile.
Through registration statements such as the Form S‑1, readers can review the company’s business overview, including its description of DurAVR THV as a balloon‑expandable biomimetic aortic valve, the role of its proprietary ADAPT tissue technology and the design of the ComASUR balloon‑expandable delivery system. These filings also outline the PARADIGM Trial, a global prospective randomized controlled trial comparing DurAVR THV to commercially available TAVR devices, and explain how the trial is intended to support a future Premarket Approval application and CE Mark progress.
Current reports on Form 8‑K document material events such as FDA IDE approval for PARADIGM, first patient enrollment and treatment in the pivotal trial, clinical data presentations, capital raising transactions involving common stock, CHESS Depositary Interests and warrants, and other corporate developments. Definitive proxy statements on Schedule 14A provide detail on the annual meeting agenda, director elections, equity incentive awards and stockholder voting procedures.
On Stock Titan, these filings are updated in near real time from EDGAR and can be paired with AI‑generated summaries that highlight key points from lengthy documents. Users can quickly locate quarterly reports on Form 10‑Q, annual reports on Form 10‑K (when filed), 8‑K event disclosures and registration statements, and use AI‑assisted explanations to understand complex sections such as risk factors, clinical trial descriptions, capital structure and equity compensation proposals.
For those analyzing AVR, the filings page offers a structured way to follow how Anteris presents its structural heart strategy, clinical evidence plans and financing arrangements to regulators and investors.
Anteris Technologies Global Corp. announced it obtained its first European regulatory clearance to commence the DurAVR Transcatheter Heart Valve Global Trial. The company furnished a press release as Exhibit 99.1.
This clearance permits initiation of the DurAVR clinical program in Europe. The information was furnished, not filed, under the Exchange Act and is not incorporated into other securities filings unless specifically referenced.
Anteris Technologies Global Corp. disclosed that after the FDA reviewed its Investigational Device Exemption (IDE) for the DurAVR® THV System, the agency requested additional information focused mainly on bench testing. The company says it has submitted a formal response addressing those requests. The IDE package submitted includes the clinical study protocol and a technology package that the company states demonstrates the device has been developed and tested for a global pivotal trial. In parallel, Anteris is pursuing regulatory submissions with competent authorities in Europe to advance the PARADIGM Trial across multiple regions.
Documented by the company’s Vice Chairman and CEO, the filing reports regulatory engagement but does not disclose timelines, specific test results, or projected trial start dates.
Anteris Technologies Global Corp. (AVR) filed a Form 8-K reporting a material event and attached a press release as Exhibit 99.1 dated September 4, 2025. The filing identifies the company as a Delaware corporation listed on The Nasdaq Global Market, provides the registrant's principal office address in Toowong, Queensland, Australia, and shows the company has elected emerging growth company status on the cover page. The 8-K cover also includes the Inline XBRL cover page flag and is signed by the company’s Vice Chairman and Chief Executive Officer, Wayne Paterson.
Anteris Technologies Global Corp. (AVR) is soliciting proxies for a virtual Special Meeting of Stockholders on September 4, 2025, to vote on two proposals: approval of an ASX Waiver and an Adjournment Proposal. Only holders of record as of August 11, 2025, may vote; 36,062,370 shares of Common Stock were outstanding as of the Record Date. The ASX Waiver, if approved, would permit the Company to seek relief from ASX limits on issuing equity (including exceeding a 15% issuance limit) for a three-year period, subject to Nasdaq rules and conditions set by ASX. The Board unanimously recommends a vote FOR the ASX Waiver. CDI holders are beneficial owners and must instruct the CHESS Depositary Nominee to vote via a CDI Voting Instruction Form. Voting deadlines and procedures for electronic, telephone, and mail voting are specified in the proxy materials.
Anteris Technologies Global Corp. received a Schedule 13G/A disclosing that Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd. and Joseph Edelman collectively beneficially own 1,705,130 shares of the issuer's common stock, representing 4.7% of the outstanding class based on 36,062,370 shares outstanding. The Master Fund directly holds the shares; Perceptive Advisors is the fund's investment manager and Mr. Edelman is the managing member, and each may be deemed to beneficially own the shares. No sole voting or dispositive power is reported; all voting and dispositive power is shared.
Anteris Technologies Global Corp. disclosed that Sio Capital Management, LLC beneficially owned 2,934,027 shares of the issuer's common stock, representing 8.14% of the class based on 36,062,087 shares outstanding. Sio reports no sole voting or dispositive power and instead holds these shares with shared voting and shared dispositive power. The filing describes Sio as a Delaware-registered investment adviser acting for affiliated funds that directly hold the shares, and notes that Sio GP, LLC and Michael Castor may be deemed to have control but expressly disclaim beneficial ownership.
Anteris Technologies Global Corp. (AVR) reported continued development-stage results as it scales toward a pivotal US trial. Net sales were $0.6 million for Q2 2025 and $1.17 million for the six months, while operating investment drove a loss after tax of $42.99 million for the six months ended June 30, 2025. Cash declined to $28.4 million from $70.5 million at year-end 2024 as operating cash outflows totaled $41.0 million in H1 2025.
The company increased R&D spending to $32.8 million for H1 2025 to scale manufacturing and prepare the PARADIGM randomized pivotal trial; 79 sites are qualified for that study. Anteris completed a U.S. IPO and received net proceeds of $80.0 million (including the over-allotment), but management discloses substantial doubt about the company’s ability to continue as a going concern without additional capital.
Anteris Technologies Global Corp. (Nasdaq AVR) has filed a PRE 14A calling a fully virtual special meeting for 4 Sep 2025.
Shareholders will vote on: (1) ASX’s three-year waiver of Listing Rule 7.1, allowing equity issuances above the current 15 % cap without prior ASX shareholder approval, and (2) authority to adjourn the meeting to gather more proxies if Proposal 1 lacks support.
The board argues the waiver aligns AVR with U.S. peers and provides funding flexibility for the DurAVR THV program, while Nasdaq’s 20 % and change-of-control rules will still govern large deals.
Proposal 1 needs 75 % of votes cast; Proposal 2 needs a simple majority. Illustrative scenarios show potential shareholder dilution from 8 % up to 73 %, depending on deal size and price. Record date is 11 Aug 2025; CDI holders must instruct CDN to vote on their behalf.
The board unanimously recommends voting FOR both proposals.
FAQ
What is the current stock price of ANTERIS TECHNOLOGIES GLOBAL (AVR)?
What is the market cap of ANTERIS TECHNOLOGIES GLOBAL (AVR)?
